Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Baron Health Care Fund stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its Q4 2024 investor letter: “Shares of UnitedHealth Group Incorporated (NYSE:UNH), the ...

Despite recent struggles, I maintain a buy rating on UnitedHealth Group due to its compelling valuation and strong revenue and earnings forecasts. UNH's Q4 results showed mixed performance ...

Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, ...

The move to exit its previous Medicare Advantage agreement with UnitedHealthcare, as well as the hurricanes that struck the ...

We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

With Q4 behind us, let’s have a look at UnitedHealth (NYSE:UNH) and its peers. Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on ...